


Claims

1. (Previously Presented) A method of treating a condition which is ameliorated by inhibiting or decreasing serine protease activity of matriptase or membrane-type serine protease 1 in a mammal in need of treatment which comprises administering to said mammal a therapeutically effective amount of a compound which inhibits serine protease activity of matriptase or membrane-type serine protease 1 wherein said compound is selected from the group consisting of:

(1)



;

(2)




;

(3)




;

(4)




;

(5)




;

(6)




;

(7)




;

(8)




;

(9)




;

(10)




;

(11)




;


(12)




(13)




(14)



(15)




(16)




;

(17)




;

(18)




;

(19)




;

(20)




;

(21)




;

(22)



; and

(23)




2. (Previously Presented) A method according to claim 1 wherein said compound has an  $IC_{50}$  for inhibition of serine protease activity of matriptase or membrane-type serine protease 1 of 100 nM or less.

Claim 3 (Cancelled).


4. (Previously Presented) A method of treating a condition which is ameliorated by inhibiting or decreasing serine protease activity of matriptase or membrane-type serine protease 1 in a mammal in need of treatment which comprises administering to said mammal a therapeutically effective amount of a compound which selectively inhibits serine protease activity of matriptase or membrane-type serine protease 1 wherein said compound is selected from the group consisting of:

(1)




;

(2)




;

(3)




;

(4)




;

(5)




;

(6)




;

(7)




;

(8)




;

(9)



;


(10)



;




(11)




;

(12)




;

(13)




;

(14)




;

(15)




;

(16)




;

(17)




;

(18)




;

(19)




;

(20)




;

(21)


*i*

(22)




; and

(23)




5. (Previously Presented) A method according to claim 4 wherein said compound has an IC<sub>50</sub> for inhibition of serine protease activity of matriptase or membrane-type serine protease 1 of 100 nM or less.

6. (Previously Presented) The Compound of the formula:



7. (Previously Presented) The Compound of the formula:



Claims 8 to 15 (Cancelled).